pharma & biopharma



Analytical Power Reduces Time to Market

Biotherapeutics are on the rise, growing at doubled digits and are predicted to represent more than 50% of the pharmaceutical pipeline in 2022. Bruker is uniquely positioned to tackle the complexity of biologics and biosimilars structures and their characterisation. With a wide variety of techniques, methods, and applications we delivery complementary data that enhances the overall knowledge of the biotherapeutic and aids decision-making. These applications range from high order structure fingerprinting, potency, intact mass and post-translational modification determination, moisture, and aggregation analysis, bioproduction analytics, impurity profiling and shelf-life.

Technology leaders in MS, NMR and vibrational spectroscopy, Bruker’s instrumentation provides the superior data needed to reduce trials, risks, and time to market.  Bruker supports biologics and biosimilar manufacturers to confidently gain crucial structural insights and knowledge about their drug candidates, enabling the timely and cost-effective discovery, development, and production of tomorrow’s medicines.